Anti-EGFR Reintroduction and Rechallenge in Metastatic Colorectal Cancer (mCRC): A Real-World Analysis

Area of Science:

• Oncology
• Medical Research
• Clinical Trials

Background:

• Anti-epidermal growth factor receptor (EGFR) antibodies are standard treatments for Rat sarcoma proto-oncogene (RAS) wild-type metastatic colorectal cancer (mCRC).
• Limited treatment options exist upon disease progression, leading to increased use of anti-EGFR re-exposure in clinical practice.
• Assessing the real-world utility of anti-EGFR retreatment is crucial for managing mCRC.

Purpose of the Study:

• To evaluate the clinical implementation and effectiveness of anti-EGFR retreatment strategies in real-world mCRC patients.
• To compare outcomes between anti-EGFR rechallenge and reintroduction after initial therapy.

Main Methods:

• A monocentric retrospective study included 524 patients with colorectal cancer (CRC).
• Patients receiving anti-EGFR-based treatment were identified, including those undergoing rechallenge or reintroduction.
• Data on overall survival (OS) and progression-free survival (PFS) were analyzed.

Main Results:

• Anti-EGFR re-exposure in 33 patients showed a trend towards better OS (56.0 vs. 35.4 months, p=0.06) compared to no re-exposure.
• Reintroduction subgroup (n=12) demonstrated a trend towards higher OS and PFS compared to the rechallenge subgroup (n=21).
• The primary chemotherapy used during re-exposure was FOLFIRI (39.4%).

Conclusions:

• Real-world evidence suggests that anti-EGFR re-exposure strategies can benefit mCRC patients.
• The benefit appears independent of the reason for prior anti-EGFR discontinuation.
• Further investigation into reintroduction versus rechallenge strategies is warranted.